Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Research context
Zynex Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Distribution
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Zynex, Inc is currently in a long term downtrend where the price is trading 3.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Zynex, Inc's total revenue rose by 80.8% to $26M since the same quarter in the previous year.
Its net income has dropped by 39.4% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 192.9% to $-2M since the same quarter in the previous year.
Based on the above factors, Zynex, Inc gets an overall score of 2/5.